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Background: Organic nitrates uncouple bone turnover, improve bone mineral density, and improve trabecular and
cortical components of bone. These changes in turnover, strength and geometry may translate into an important
reduction in fractures. However, before proceeding with a large fracture trial, there is a need to identify the nitrate
formulation that has both the greatest efficacy (with regards to bone turnover markers) and gives the fewest
headaches. Ascertaining which nitrate formulation this may be is the purpose of the current study.
Methods and design: This will be an open-label randomized, controlled trial conducted at Women’s College
Hospital comparing five formulations of nitrates for their effects on bone turnover markers and headache. We will
recruit postmenopausal women age 50 years or older with no contraindications to nitroglycerin. Our trial will
consist of a run-in phase and a treatment phase. We will enroll 420 women in the run-in phase, each to receive all
of the 5 potential treatments in random order for 2 days, each with a 2-day washout period between treatments.
Those who tolerate all formulations will enter the 12-week treatment phase and be randomly assigned to one of
five groups: 0.3 mg sublingual nitroglycerin tablet, 0.6 mg of the sublingual tablet, a 20 mg tablet of isosorbide
mononitrate, a 160 mg nitroglycerin transdermal patch (used for 8 h), and 15 mg of nitroglycerin ointment as used
in a previous trial by our group. We will continue enrolment until we have randomized 210 women or 35 women
per group. Concentrations of bone formation (bone-specific alkaline phosphatase and procollagen type I N-terminal
propeptide) and bone resorption (C-telopeptides of collagen crosslinks and N-terminal crosslinks of collagen) agents
will be measured in samples taken at study entry (the start of the run in phase) and 12 weeks. Subjects will record
the frequency and severity of headaches daily during the run-in phase and then monthly after that. We will use the
‘multiple comparisons with the best’ approach for data analyses, as this strategy allows practical considerations of
ease of use and tolerability to guide selection of the preparation for future studies.
Discussion: Data from this protocol will be used to develop a randomized, controlled trial of nitrates to prevent
osteoporotic fractures.
Trial registration: ClinicalTrials.gov Identifier: NCT01387672. Controlled-Trials.com: ISRCTN08860742.
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Organic nitrates, medications used to treat angina, have the
potential to reduce the morbidity, mortality and costs asso-
ciated with osteoporotic fractures. The comparative effects
of available nitrate formulations have not been studied.
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reproduction in any medium, provided the orbeen compared. Their effects on headaches, the most com-
mon adverse effect that limits their use, have not been eval-
uated. Therefore, we propose to compare several widely
available nitrate formulations for the efficacy on markers of
bone formation and resorption and for the number and se-
verity of headaches they cause.
We have found that application of 15 mg of nitrogly-
cerin ointment at night has unique and substantial effects
on bone. Our work has demonstrated that nitroglycerintd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mation and decreases bone resorption [1]. This uncoupling
leads to substantial increases in bone density, improve-
ments in bone geometry, and increases in indices of bone
strength by peripheral quantitated computed tomography
(pQCT). These effects are stronger than have been ob-
served for current treatments including bisphosphonates
and parathyroid hormone.
Nitrates are an attractive therapy for osteoporosis be-
cause they are inexpensive and universally available. Fur-
ther, in contrast to currently available treatments (which
affect trabecular bone and primarily result in a decrease
in vertebral fractures), our preliminary data suggest that
nitrates also increase cortical bone density and strength.
As such, nitrates, more than the available therapies, have
the potential to decrease the fracture rates that occur in
cortical bones (such as the hip, leg, forearm, and upper
arm). These fractures are extremely common and are as-
sociated with disability and death.
A randomized trial with fracture endpoints is essential
to establish the efficacy of nitrates for clinical use. De-
signing a fracture-prevention trial requires choosing a
preparation and dose of nitrate that maximizes its bene-
ficial effects on bone while minimizing adverse effects.
Several nitrate formulations are already widely available
and several are generic. As such, it is highly unlikely that
a pharmaceutical company will invest in the develop-
ment and clinical testing of available formulations. Thus,
we must rely on Canadian Institutes of Health Research
(CIHR) and other agencies' funding to select best prep-
aration and test its efficacy and safety.
Before proceeding with a fracture trial, it is critical to
identify the nitrate formulation that gives the greatest ef-
fects on bone turnover, with the fewest headaches, and
is easy to use. After systematically considering the avail-
able formulations and doses, we propose to test five ni-
trates: 15 mg of nitroglycerin (NTG) ointment nightly
(whose efficacy and safety we have established), 0.3 mg
and 0.6 mg of sublingual NTG, 20 mg of isosorbide
mononitrate (ISMO), and 160 mg of glycerol trinitrate
(Nitro Dur), a patch worn overnight for 8 h.
In a randomized trial with 210 postmenopausal women,
we will ask 2 principal research questions: (1) What are
the effects of 5 formulations and doses of nitroglycerin on
2 markers of bone formation (serum bone specific alkaline
phosphatase (BALP) and procollagen type I N-terminal
propeptide (P1NP)) and 2 markers of bone resorption
(serum C-telopeptide (CTX) and urine N-telopeptide
(NTX)) over 12 weeks? And (2) How do the five formula-
tions and doses of nitroglycerin compare with regard to
frequency and severity of headaches?
We hypothesize that that there are one or two formu-
lations that are less messy, more convenient to use, re-
sult in a similar or lower rate of headaches, and increasemarkers of bone formation and decrease markers of re-
sorption at least as much as the ointment. We expect to
arrive at a consensus about the best preparation to use
in larger clinical trials designed to test the efficacy of ni-
trates for fracture prevention.
Osteoporosis (OP) is characterized by a reduction in
bone mass and disruption of skeletal microarchitecture
leading to an increased susceptibility to fracture with min-
imal trauma. OP fractures are costly to treat, cause pain,
disability, and occasionally, premature death [2]. In
Canada, one in four women and one in eight men have OP
and in 1993 the total expenditure for fractures was in ex-
cess of CA$1.3 billion [3,4]. The average length of stay in
an acute care hospital after a hip fracture is 3 weeks; one in
four patients remain in long-term care institutions for at
least 1 year; one in three returns home, but must depend
on other people or devices for mobility. Further, after a hip
fracture there is up to a 20% increased risk of mortality. As
older men and women are the fastest growing group in the
world and the frequency of OP fractures increases expo-
nentially with age, the number of men and women with
OP fractures is expected to increase dramatically over the
next 50 years in Canada and worldwide [5]. For example, if
we assume, based on current demographic trends, that the
age-adjusted frequency rates of hip fracture stabilized in
Europe and North America but rose by 3% per year in the
rest of the world, the frequency of hip fractures worldwide
could exceed 21 million in 2050 [6]. The most effective
way to moderate increases in healthcare costs, sickness,
and premature death associated with OP fractures is to
prevent OP.
Current medications include the antiresorptives: estrogen
replacement therapy (ERT), bisphosphonates (alendronate,
risedronate, zoledronic acid, and etidronate), selective estro-
gen receptor modulators (raloxifene) and denosumab,
which is a fully human monoclonal antibody to the recep-
tor activator of nuclear factor-κB ligand (RANKL). These
medications decrease bone resorption, which slows or pre-
vents bone loss. All of these agents also decrease bone
formation. Consequently, they have little effect on the
thickness and strength of cortical bone and limited (20% to
30%) reductions in the risk of non-vertebral fractures. Ral-
oxifene has no effect on the risk of non-vertebral fractures.
The only available treatment that stimulates bone forma-
tion, parathyroid hormone, also increases bone resorption.
The increased formation wanes over 12 to 18 months of
use. It improves bone mineral density (BMD) perhaps more
than do antiresorptive agents and reduces the risk of verte-
bral and non-vertebral fractures. However, its cost and need
for injection have substantially limited its use.
Each medication has adverse effects. Denosumab has
only been approved for 1 year in Canada and long-term
data (>5 years) are lacking; it is a biologic agent and con-
cerns have been raised about an increased frequency of
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of the bisphosphonate alendronate reported that at 2 years
60% of participants were adherent [8]. Bisphosphonates, if
taken improperly, can cause gastrointestinal irritation and
esophageal ulceration [9,10]. In addition, bisphosphonates
cannot be prescribed for patients with impaired renal clear-
ance, yet these patients are at particularly high risk for frac-
tures [11]. More recently, there have been concerns
about the occurrence of fractures in the lateral femur,
so-called atypical fractures, associated with the use of
bisphosphonates for more than 3 years [12]; in response
to this, concern Health Canada has mandated a warning
about atypical fractures be placed in the product label
for all bisphosphonates. Estrogen (with or without a
progestin) reduces the risk of all types of fractures by
25% to 33%, but with risks that outweigh its potential
benefits for fractures in the vast majority of women
[13]. Raloxifene is a weak antiresorptive that does not
decrease the risk of non-vertebral fractures [14]. It is as-
sociated with a three times higher rate of thrombo-
embolic disease, an increase in hot flushes, leg cramps,
leg swelling, and an influenza-like syndrome [14,15].
Parathyroid hormone is prescribed as a daily subcutane-
ous injection, and cannot be used for longer than 24
months in part due to concerns of osteosarcoma [16].
In addition to the adverse effects, most of these treat-
ments are expensive: parathyroid hormone can cost up-
ward of CA$30,000 for a 2-year course of treatment and
the antiresorptive agents (with the exception of estrogen
and alendronate) cost more than CA$700/year, are either
unavailable or unaffordable outside of North America
and Western Europe, and of uncertain safety when used
long term (>10 years).
The limitations of the current therapies have fuelled
interest in alternatives. An optimal agent would be one
that decreases bone resorption while also increasing
bone formation, BMD, cortical bone mass, and with po-
tential to decrease non-vertebral fractures more than do
existing treatments. It would be convenient to take, in-
expensive, have minimal adverse effects, be safe for
long-term use, and would be available worldwide.
Current treatments have similar and limited mecha-
nisms of action. In usual bone remodeling, resorption by
osteoclasts signals, and is coupled with, subsequent bone
formation by osteoblasts (thus bone turnover is coupled);
generally speaking, bone turnover occurs at a higher rate
in trabecular bone (the spine) than in cortical bone (the
hip). All the antiresorptive agents decrease bone resorp-
tion but also decrease bone formation, and because they
have greater effects at sites of highest turnover, they have
a greater impact on trabecular versus cortical bone. The
mode of action of antiresorptives has at least two import-
ant clinical implications: there is a ceiling with regards to
the amount of bone that can be gained and antiresorptivespredominantly decrease only the risk of vertebral frac-
tures, which occur in trabecular bone [17,18]. However,
non-vertebral fractures which typically occur in cortical
bone (including fractures of the hip, legs, upper arms and
forearms) account for most of the morbidity, mortality
and costs due to fractures [19] and even the most potent
antiresorptive drugs reduce the risk of non-vertebral frac-
tures by less than one-third [7,20-24]. Parathyroid hor-
mone (PTH) is the only therapy that increases bone
formation (but it also increases bone resorption). It re-
duces vertebral fracture risk by about 70% and may de-
crease the risk of some cortical fractures, but has not been
shown to reduce the risk of hip fractures [16].
To decrease the disability, death and medical costs due
to osteoporosis it is essential to identify an inexpensive,
widely available treatment that both increases bone forma-
tion and decreases bone resorption and thereby increases
cortical thickness and the bending strength of largely cor-
tical bones. We believe that nitric oxide, in the form of or-
ganic nitrate, may have many of these attributes.
Nitric oxide (NO) is a short-lived free radical involved
in the regulation of many physiological processes, in-
cluding bone remodeling [25,26]. There are three
sources of NO (Figure 1). NO can be generated by
the nitric oxide synthase (NOS) enzymes from molecular
oxygen and the terminal nitrogen of the amino acid L-
arginine [25,27]. NO can be generated non-enzymatically
from nitrite in the acid environment of the stomach, and
organic nitrates (for example, nitroglycerin (NTG), iso-
sorbide mononitrate (ISMO), isosorbide dinitrate) can act
as NO donors [28].
Research to date
Data from both cellular and animal studies support the
use of nitric oxide for treatment of postmenopausal
osteoporosis. Nitric oxide can inhibit osteoclast activity
and acts as a signaling molecule in osteoblasts and oste-
ocytes [29-35]. In vitro studies demonstrate that NO has
a biphasic effect on osteoclast activity and bone resorp-
tion [29,32,33,35,36]; low concentrations potentiate bone
resorption while high concentrations inhibit activity
[30,34,37]. The effects of NO on osteoblasts are less well
characterized. Some, but not all, studies report that low
concentrations of NO stimulate osteoblast growth and
differentiation [38]. Further, mice lacking nitric oxide
synthase have defective bone formation due to defects in
osteoblast differentiation and function [39,40], indicating
that NO plays a key role in regulating bone formation.
NTG ointment, an NO donor, prevents bone loss in rats
[41]. Ovariectomized rats were treated with vehicle, 17-β
estradiol, NTG ointment, or a combination of 17-β estra-
diol and NTG. Compared with baseline, treatment with
NTG increased BMD in ovariectomized rats (mean ± SD =
25 ± 2% to levels similar to those found in sham operated
Figure 1 Sources of nitric oxide.
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ovariectomized rats treated with NTG ointment (mean ±
SD = 20 ± 3%) was greater than the increase in ovariecto-
mized rats treated with vehicle (mean ± SD = 8 ± 3%)
(Additional file 1). This suggests that nitrates, which act as
NO donors, might preserve or even increase bone mass.
Supportive of this concept are data from observational and
randomized trials, reviewed below.
In 1998, we began investigating the relationship between
the use of nitrates and BMD in humans using data from
the Study of Osteoporotic Fractures (SOF), a multicenter,
prospective, observational study of 9,704 ambulatory,
Caucasian women, aged 65 years and older [42]. We hy-
pothesized that women taking nitrates intermittently would
have significantly higher bone mass than those who took
nitrates continuously. Continuous exposure to organic ni-
trate causes tachyphylaxis to its vascular effects. Data from
the cardiovascular literature report tachyphylaxis to nitrates
with increasing frequency of dose [43,44]. Tachyphylaxis to
nitrates may develop in bone: rats given NTG ointment
daily for 12 weeks had increases in BMD similar to those
with estrogen, yet more frequent administration abolished
any beneficial effects (Additional file 1) [45].
We compared hip and heel BMD among nitrate users
(391 women) and non-users (5,827 women) identified by
self-report. Women who reported using ISMO, isosorbide
dinitrate, or NTG more than once a day, every day, were
classified as continuous users (n = 317), and all other
women were classified as intermittent users (n = 74).
Compared with non-users, nitrate users were more likely
to have risk factors for low BMD [46]. After adjusting for
these differences, and for estrogen use, we found that hip
BMD was 2.6% higher and heel BMD was 5.3% higher
among intermittent nitrate users compared to non-users,
and intermittent nitrate users had greater BMD than con-
tinuous users at both these sites (Additional file 1). The re-
sults were consistent with our hypothesis that intermittent
use of nitrates improves bone mass while continuous ni-
trate use may lead to tachyphylaxis.There are two alternate explanations as to why inter-
mittent nitrate use is associated with greater BMD than
continuous use. First, women who use nitrates intermit-
tently may have better health and fewer risk factors for
low BMD than women who require continuous nitrates.
However, adjusting for known differences in health sta-
tus did not mitigate the nitrate effect. Second, the find-
ings may be due to chance variation. However, the
results were robust and statistically significant when we
examined BMD at both the hip and the heel.
The mean dose of nitrate among women reporting
intermittent use was 0.2 mg/day of NTG. This is well
below the doses required for angina treatment: a typical
single dose is 0.3 mg and daily doses vary from 0.3 mg to
0.9 mg. Among the 74 women reporting intermittent use,
the type (ISMO, isosorbide dinitrate and NTG), the form
(sublingual tablet or spray, oral tablets, sustained release
tablets, transdermal patch, or ointment) and the dose
varied.
Of note, there have been two previous case-control
studies that have reported on the effect of organic nitrates
on fracture risk [47,48]. Both of these studies demonstrate
that nitrate use was associated with a decreased risk of
fracture, including hip fracture (by about 10% to 15%),
and that the reduction in fracture risk was greatest among
those using low-dose nitrates on as needed basis. How-
ever, these studies were unable to compare formulations
with regard to efficacy or headaches.
These findings, considered together with findings from
our previous study [42], suggest an intriguing possibility:
that nitrates of any formulation administered intermittently
can increase BMD and decrease the risk of fractures, par-
ticularly the risk of non-vertebral fractures. However, we
have not identified the most potent treatment and one that
causes headaches least frequently. This research proposal
will make these comparisons and set the stage for a trial to
test the antifracture efficacy of nitrates.
The next step in our program of research was a RCT
comparing the effects of placebo and intermittent ISMO
on markers of bone turnover in postmenopausal women.
We randomly assigned 144 women (≥3 years postmeno-
pausal with femoral neck BMD T-scores between 0 and
-2.5) to 12 weeks of placebo or intermittent ISMO of 5
mg or 20 mg per day; typically, ISMO is prescribed at 20
mg twice a day. We measured changes from baseline in
urine N-telopeptide (NTx), a marker of bone resorption
and serum bone-specific alkaline phosphatase (BSAP), a
marker of bone formation [49].
Our earlier work suggested that the effect of nitrates
on bone was a class effect and as such we did not think
the formulation nitrate we chose would result in sub-
stantially different effects on markers of bone turnover
as long as it was given intermittently and in a low dose
[42]. We chose to study ISMO because it is completely
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fect, has linear dose-dependent pharmacokinetics, and
marked dose-dependent hemodynamic effects [50]. We
chose doses of 5 mg and 20 mg; pharmacologic data
demonstrate that the threshold of oral activity of ISMO
is 5 mg and the maximum response is reached with
doses of 20 mg [43]. To prevent tachyphylaxis [44], we
gave ISMO, which is typically administered twice a day,
once a day or intermittently. We found that, compared
with placebo, women randomized to intermittent ISMO
at 20 mg had a 45.4% decrease in NTx (95% confidence
interval (CI) 25.8 to 64.9) and a 23.3% increase (95% CI
8.9 to 37.8) in BSAP. Women randomized to intermit-
tent ISMO at 5 mg had a 36.3% decrease in NTx (95%
CI 14.8 to 57.8) and a 15.9% increase in BSAP (95% CI
1.1 to 30.7) (Figure 2) [49].
The decreases in NTx that we observed with 20 mg of
ISMO are similar to those reported with alendronate,
risedronate, and estrogen (about 50%) and greater than
the 25% decreases reported with raloxifene [51,52].
However, all of the antiresorptive agents concomitantly
decrease rates of bone formation. In contrast, we ob-
served that treatment with ISMO resulted in significant
increases in BSAP.
The decrease in resorption, coupled with the increase in
formation, suggests that ISMO may reduce fracture risk to
an even greater degree than that seen with the current
antiresorptive agents. The only adverse event was head-
ache. Headaches were more common among women ran-
domized to ISMO (5 and 20 mg groups combined n = 55,
57%) compared with placebo (n = 2, 4%; P = 0.004). Head-
aches were no more common among women taking 20
mg of ISMO (50.9%) than among women taking 5 mg of
ISMO (49.09%; P = 0.7).
Only one other randomized trial has examined the ef-
fects of nitrates on bone. This was an open-label trial
that randomized 16 oophorectomized women, aged 36
to 45 years, to intermittent NTG ointment (15 mg/day)Figure 2 Percentage change in urine N-telopeptide (NTx) and
serum bone-specific alkaline phosphatase (BSAP) in women
randomly assigned to 5 or 20 mg of isosorbide mononitrate
(ISMO) daily compared to women assigned to placebo.or oral conjugated estrogen (0.625 mg) [41,53]. After 6
months, women taking NTG ointment had a 40% decrease
in NTx and 25% increase in BSAP compared with baseline.
The magnitude of change in bone turnover markers was
similar to what we found with ISMO: consistent with the
concept that the effects of nitrates on bone might be inde-
pendent of the formulation. The number of headaches was
not reported, however personal communication with the
primary investigator (Dr. Sunil J Wimalawansa) indicted
that there was no dropout due to headaches in this study.
The magnitude of effects on bone markers and the un-
coupling between formation and resorption was similar
for both NTG and ISMO. The lack of headaches with
NTG deserved further study and this served as the basis
for our next research project: ‘A CIHR funded study with
two placebo controlled trials: a four week pilot study
and a 27 month main study in healthy postmenopausal
women’. The aim of the pilot study was to determine
the best tolerated preparation of nitrate for future stud-
ies. Specifically, we assigned 22 subjects to intermittent
NTG at 15 mg/day and intermittent ISMO at 20 mg/
day, each for 1 week. The order of the treatments was
random, accompanied by a placebo control (identical in
sight and smell to the active treatment). Inbetween each
treatment, there was a 2-week washout period. Subjects
recorded the severity of headaches upon awakening
every day for 4 weeks using a visual analogue scale
(VAS). We calculated the mean headache score for each
subject over both 7-day treatment periods and then the
mean headache score, considering all subjects for each of
the NTG and ISMO treatment periods. We found that the
ISMO was associated with more frequent headaches (12
women reported daily headaches vs 5 women) and more
severe headaches than the NTG ointment (mean headache
score: 4/5 for ISMO vs 2/5 for NTG ointment) [54]. As a
result, we used the NTG ointment for our next study
reviewed below [1]. To limit differential dropout due to
headaches, the main trial followed from a 1-week nitrate
run-in phase; women who discontinued the nitrate due to
headaches did not enter the main trial.
Our trial was designed to test the effects of nitroglycerin
on bone turnover, density, geometry, and strength. We
randomly assigned 243 postmenopausal women with
BMD T-scores between 0 and -2.0 at the lumbar spine
to 15 mg of NTG ointment or placebo daily at bedtime
for 24 months. We examined four outcomes: BMD,
pQCT, bone turnover and headaches. We found that at
2 years, compared with placebo, NTG increased spine
BMD 6.7% (95% CI 5.2 to 8.2; P <0.001), femoral
neck BMD 7.0% (95% CI 5.5 to 8.5%; P <0.001) and total
hip BMD 6.2% (95% CI 5.2 to 7.3; P <0.001) [54]. This pat-
tern is unique. All current treatments improve spine BMD
(largely trabecular) more than femoral neck BMD (largely
cortical). These results suggest that NTG has uniquely
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into greater effects on the risk of non-vertebral fractures.
We also found that at the radius and the tibia, respect-
ively, 2 years of NTG increased cortical thickness (13.9%
and 24.6%), cortical area (10.6% and 10.0%) and perios-
teal circumference (7.4% and 2.9%), with small effects on
cortical density. This pattern indicates that nitroglycerin
increases cortical bone mass; the increase in periosteal
diameter suggests that it may induce formation of new
bone on the periosteal surface, a biologically unique ef-
fect not observed with antiresorptives. As would be
expected from these effects on cortical bone, NTG in-
creases indices of strength: section modulus or bone
bending (10.7% and 9.8%), and polar moment of inertia
or bone twisting (7.3% and 14.5%) at the radius and tibia
respectively [54]. These improvements in bone strength
indicate that NTG should decrease the incidence of
non-vertebral fractures.
NTG ointment uncoupled bone formation from bone
resorption. At 2 years, the BALP levels increased by 36%
and the NTX levels decreased by 51%, the results being
statistically significant [1]. Unlike treatment with PTH, the
magnitude of bone formation continued to increase over 2
years.
The most common adverse effect we observed was
headache. During a 1-week run-in phase with 15 mg of
NTG ointment, 104 of 400 women stopped treatment
because of headache. Among those who continued into
the randomized trial, seven in the NTG and two in the
placebo group stopped treatment during the 2 years be-
cause of headaches. Although 36% of women receiving
NTG reported a headache during the first 6 months of
the trial, headache was uncommon by 2 years (1.7% in
the nitroglycerin vs none in the placebo group).
Of note, a recent randomized trial of once-daily NTG
ointment (Nitro-Bid 22.5 mg) did not find increased
BMD at the lumbar spine, femoral neck of total hip.
However, adherence to treatment was poor and there
were additional concerns about the quality control of
the bone density endpoints [55].
Considered together, our data, even in the light of the
negative study suggest that changes in cortical bone geom-
etry caused by NTG ointment may translate into an im-
portant reduction in fractures: non-vertebral fractures,
such as hip fractures, in particular. Further, there might be
an even greater risk reduction in all fractures compared
with the currently available osteoporosis treatments. How-
ever, before proceeding with a large randomized con-
trolled trial to determine if nitrates can reduce fractures
we need to conduct a dose ranging study that will lead to
the identification of a nitrate preparation that is easy to
use and gives the lowest frequency of headaches together
with the greatest changes in bone turnover markers. This
is the purpose of the current research proposal.Methods and design
The proposed trial
This will be an open-label randomized trial comparing
five formulations of nitrates for their effects on bone
turnover markers and headache. Because we will com-
pare our results to our previous CIHR funded trial of
NTG ointment, we have designed the trial to be as simi-
lar as possible to that earlier trial in study location, en-
rolment of the subjects, and choice of endpoints. We
will recruit postmenopausal women age 50 years or
older with no contraindications to using nitroglycerin
(NTG). Our trial will consist of two phases. A run-in
phase and a treatment phase, outlined below.
There are at least 13 nitrate formulations, each with
varying doses. The comparative effects of available nitrate
formulations have not been studied. Their effects on bone
formation and resorption have not been compared. Their
effects on headaches, the most common adverse effect,
have not been evaluated and there are no data comparing
the pharmacokinetics and little laboratory work relevant
to selection of preparation or dose. Cellular, animal and
human data suggest that effect of nitrates on bone is inde-
pendent of formulation, but the dose should be low and
the formulation used intermittently. However, it is possible
that there might be some formulations that are preferred
over others and the number of headache may vary by for-
mulation. As such, before proceeding with a fracture trial,
it is critical to identify the nitrate formulation that gives
the greatest effects on bone turnover, with the fewest
headaches, and is easy to use.
In selecting the formulations and doses to be tested in
the current study we consulted with a group of scien-
tists, including a cardiologist, a scientist who conducts
cellular research in the area of nitric oxide, an internist,
and a pharmacist/chemist. Our selections of formula-
tions and dose were guided by several considerations.
First, although we found strong effects of NTG ointment
on bone, it is not an ideal preparation: approximately 2.5
cm (1 inch) is squeezed onto paper that is then taped to
the skin. Participants complained of messiness, the paper
sometimes falling off during sleep, and the dose being
varied with different amounts squeezed onto the paper.
Second, we include the 20 mg tablet of ISMO because it
is convenient: we have previously shown that it increases
markers of formation and decreases makers of resorp-
tion, and while it was a different study with a different
design, the dropout due to headaches among women
randomized to ISMO (20%); far less than what we ob-
served during the run in phase with NTG ointment
(about 40%) [48,54]. Third, we will use formulations that
last 8 h or less because the sensitivity to effects of ni-
trates decreases with increasing frequency of dosing and
continuous use (tachyphylaxis) [44]. Our data from the
SOF found that women using nitrates intermittently had
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continuously [41]. Fourth, we have included sublingual
tablets that produce a rapid peak effect because of the
possibility that agents that induce bone formation might
have greater effects if they rapidly reach peak levels with
rapid offset, as has been shown for teriparatide [15]. This
formulation was the most common one used by women
taking intermittent nitrates in the SOF study. Fifth, we
included a patch because it may have similar absorption
of NTG as ointment but avoids the messiness. To pre-
serve the 8-h duration, and minimize tachyphylaxis, we
chose the highest-dose patch but will ask subjects to re-
move it by 8 versus 12 h. Finally, we will give the nitrate
at bedtime as our earlier work demonstrated that taking
the nitrate at bedtime resulted in a lower frequency of
headaches than when taken in the morning.
We will start with a run-in phase to exclude women
who would be unable to start the main trial because of
headache. We will enroll about 420 women in the run-in
phase, each to receive all of the 5 potential treatments
(see below) in random order for 2 days each with 2-day
washout period between treatments for a total of 18
days. The washout exceeds 10 half-lives of all of our for-
mulations (which vary from 32 minutes in the case of
sublingual NTG to 8 h for transdermal ointment) and
will eliminate any carry-over effects [56-59].
Subjects will be seen at the start of the run in phase. We
will take blood and urine for markers of bone turnover.
Subjects will be given written and verbal instructions
concerning the order of their treatment assignments, dur-
ation of the wash-out period and how to complete the
VAS. We will also call subjects once at the start of the run
in phase to confirm that the instructions have been under-
stood and are being followed.
Those who tolerate all five formulations will enter the
treatment phase and be randomly assigned to one of six
groups: 0.3 mg sublingual nitroglycerin tablet, 0.6 mg
of the sublingual tablet, a 20 mg tablet of isosorbide
mononitrate, a 160 mg nitroglycerin transdermal patch
(to be used for 8 instead of 12 h), and 15 mg of the
NTG ointment used in the previous trial. To assure that
the NTG ointment has the effects observed in our previ-
ous trial, we will also include a sixth randomized group
to receive matching placebo ointment applied at night
for about 8 h. All women will be randomized to receive
one of the five formulations (or placebo) according to
the randomization list provided by the study pharmacist
(Sunnybrook Hospital, Toronto, Ontario, Canada). Wo-
men receiving the ointment formulation are blinded on
whether they received the active NTG ointment or pla-
cebo. They will be unblinded, if they wish, upon study
completion. We will continue enrolment until we have
randomized 210 women, about 35 women per group.
Concentrations of bone formation (BALP and P1NP)and bone resorption (CTX and NTX) will be measured
in samples taken at study entry (at the start of the run in
phase) and at 12 weeks. Subjects will record the number
and severity of headaches on a daily basis during the
run-in phase and then weekly after that. According to
the product monograph, other possible events that are
reported less frequently include: postural hypotension
(lightheadedness going from lying/sitting to standing);
increased heart rate; faintness; flushing; dizziness; nau-
sea; vomiting and dermatitis (skin redness or irritation).
To date, in our clinical trials we have not noted these
less frequent adverse events. However, we will monitor
for these effects.
Subjects will be seen again at the start of the treatment
phase. At this visit, and as we did in our previous trial, we
will administer the Block food-frequency questionnaire
[60] to estimate dietary calcium and vitamin D intake and
if required provide supplemental calcium carbonate (in
500 mg tablets) and vitamin D in 400 IU tablets as needed
so that the total daily calcium intake for all study subjects
will be 1,200 mg and the vitamin D intake will be 800 IU;
these are the intakes recommended in the recently pub-
lished guidelines for the prevention and treatment of OP
in Canada [61,62]. Calcium and vitamin D are the main-
stay of all treatment regimens for OP and any new agent
should be evaluated to assess the additional benefit it
would provide. Further, by providing calcium and vitamin
D, we hope to discourage subjects who, after being enrolled
in an ‘OP trial’, start taking additional, unreported calcium
and vitamin D (cointervention). Calcium and vitamin D
will be prepared and packaged by the study pharmacist
(Sunnybrook Hospital, Toronto, Ontario, Canada), and in-
structions on how to take the supplements and the PI’s of-
fice number will be printed on each bottle. Subjects will be
given standard verbal instructions by the research assistant
and reminded to take the calcium and vitamin D daily with
the morning meal. We will also provide the subjects with
their treatment assignment and provide standard written
(on the package and a information sheet) and verbal in-
structions on how to take the treatment. The treatment as-
signment will be prepared and packaged by our study
pharmacist and the PI’s office number will be printed on
each package.
Subjects will be called twice during the treatment phase:
at 4 and 8 weeks after their visit. During these calls we will
ask about the use of any new prescription and non-
prescription medications; we will specifically ask about the
use of any drugs for the treatment of OP, and about the use
of calcium and vitamin D supplements. We will assess for
possible adverse effects using a standardized, interviewer-
administered questionnaire [63] (Additional file 1). We will
first ask about any general adverse events. We then will ask
specifically about headache, nausea, and dizziness (the three
most common side effects associated with nitrate use [42]),
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events will be followed daily until the adverse events have
resolved. We will also ask about emergency room visits,
hospitalizations, and visits to walk-in clinics (defined as se-
vere adverse events), and the reason for these visits. The
questionnaire we plan to use for assessment of adverse
events was developed and validated in healthy postmeno-
pausal women as part of SAJ’s doctoral thesis [64]. Serious
adverse events will be reviewed by the DSMB and decisions
about continuing with the treatment assignment will be
made on a case-by-case basis by the DSMB. We will see
subjects at the end of the treatment phase and at this visit
we will collect and count unused medication, calcium and
vitamin D and administer our adverse event questionnaire.
Our study design is illustrated in Additional file 1.
Our study pharmacist will use a computer-generated
random number sequence to match each study identifi-
cation number to treatment assignment for both the run
in phase and the treatment phase.
Ideally, to protect against sources of bias, all of the treat-
ments should be blinded. However, placebos for all formu-
lations are unavailable, and it is not feasible to prepare
new ones for this study. The primary outcome of change
in markers of bone turnover is unlikely to be influenced
by unblinded use of the formulations; note that technician
who measures our markers will be blinded to treatment
assignment. We recognize that reports of headaches are
subjective and might be influenced by knowing the treat-
ment assignment: a woman taking an ‘active’ drug might
be more likely to notice headaches. We will note this
potential bias as we consider the selection of the best
preparation.
The run-in phase and treatment phase will have iden-
tical inclusion and exclusion criteria (Additional file 1).
As in our previous trial, we will include women aged 50
years and older whose last menstrual period occurred at
least 3 years ago. Those without a uterus will be eligible
after age 55 years.
We will use the same exclusion criteria as in our previ-
ous trial: (1) women with a history of previous fracture; (2)
those who report a diagnosis of osteoporosis (‘osteopenia’
will not be excluded) (note that we did consider measuring
BMD at entry to the study to exclude women with low
BMD as it is not feasible within the budget; if a woman
has low BMD not identified at study entry, her risk of frac-
ture during a 12 week trial would be very low); (3) a his-
tory of disorders such as hyperparathyroidism or Paget’s
disease; (4) treatment within 12 months of study entry
with any agent that may influence bone metabolism in-
cluding any hormone, antiestrogen or raloxifene, prednis-
one (equivalent to 5 mg/day for 12 months or greater),
lithium, or serotonin reuptake inhibitors; (5) treatment
with any oral bisphosphonate, including alendronate,
risedronate or etidronate use for at least 4 weeks, withinthe last 3 years and any previous treatment with the very
long-lasting intravenous zoledronate; (6) treatment with
parathyroid hormone or denosumab within the past 12
months; (7) current treatment with nitrates; (8) any history
of migraine headaches (nitrates can exacerbate migraines);
(9) history of angina or cardiovascular disease; (10) inabil-
ity to give informed consent; and (11) hypersensitivity to
nitroglycerin.
Outcomes to be assessed
Run-in phase
During the run-in phase, subjects will receive, in random
order, each of the five nitrate formulations for 2 days with
a 2-day wash out period between formulations. We antici-
pate potential dropouts of participants both during the
run-in and prior to the intervention phase, with main rea-
son for discontinuing the study being headaches. We will
immediately discontinue participants who have severe
headaches with any of the formulations as a contraindica-
tion for any use of nitrates. To maximize efficiency and
minimize dropouts, participants will be able to continue
into the treatment phase immediately upon completion of
the run-in phase.
Subjects will record the severity of headaches upon
awakening every day during the run-in phase using a VAS
(Additional file 1). The VAS has documented reliability,
can detect subtle changes in headache and has been used
in several studies, including our earlier CIHR funded
study, designed to study the effects of NTG ointment on
headache in healthy women [54,58,59]. To help establish
the preferred preparation, every participant will be asked
to rate and rank the five formulations and write comments
about their acceptability for long-term use. We will also
use these data together with the mean headache score (for
each subject over the treatment periods and then the
mean headache score considering all subjects in each of
the treatment groups), to determine which formulations, if
any, will not be continued in the treatment phase. As we
aim to assess treatment options with reasonably broad ac-
ceptability, if there is one formulation that gives headaches
in more than 75% of subjects in the run-in phase in the
first 6 months of recruiting or is uniformly disliked in
terms of mode of application, then we will eliminate that
arm from our intervention phase. However, previous stud-
ies suggest that rate of headache will not be this high and
individual preferences are likely to vary enough to merit
consideration of effect, and we anticipate carrying forward
all formulations to the intervention phase.
Treatment phase
We will determine the percentage change, from baseline,
in two markers of bone resorption (CTX and NTX) and
two markers of bone formation (BALP and P1NP)
among each of the five treatment arms and the placebo
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and the International Osteoporosis Foundation has now
proposed that all trials include P1NP and CTX [65]. All
four markers will be measured on samples drawn at the
start of the run-in phase, as it is possible that there will
be an effect on bone turnover with the short bursts of
nitrate treatment during the run-in phase, and again
at the final 12-week visit. We will measure CTX by
electrochemiluminescence immunoassay (Roche Elecsys,
Roche Diagnostics, Germany); the interassay coefficient of
variation (CV) is 4.7%. We will measure NTX by en-
hanced chemiluminescence immunoassay (Vitros ECi,
OrthoDiagnostics, USA); the interassay CV is 7.9%. P1NP
will be measured by electrochemiluminescence immuno-
assay (Roche Elecsys, Roche Diagnostics); the interassay
CV is 9.1%. BALP will be measured by paramagnetic par-
ticle immunoassay (Access 2, Beckman Coulter); interassay
CV: 7.5% [66]. To minimize variability, we will collect
fasting serum samples and second morning urine samples,
store them at -70°C, and analyze all the samples together in
a single laboratory at study completion.
Note that bone turnover markers allow us to assess
the effects of treatment by 12 weeks. We recognize that
bone markers are biomarkers for the clinical outcome of
interest (fracture). However, a phase II trial of dose se-
lection using change in BMD or bone geometry as end-
points would be prohibitively large, long, and expensive.
Further, recent data suggest that higher levels of some
bone resorption markers predict fractures independently
of BMD [67,68] and with antiresorptive therapy greater
treatment-related decreases in bone turnover are associ-
ated with a decreased risk of vertebral and non-vertebral
fracture [69,70].
Note that all our trial protocol has and will continue
to be conducted in accordance with the Helsinki declar-
ation [71]. Our protocol has been reviewed and ap-
proved by the appropriate institutional research ethics
boards (Women’s College Hospital and The University
of Toronto) and all subjects are required to provide writ-
ten informed consent before participating in our study.
Sample size and analyses
We will use the ‘multiple comparisons with the best’
(MCB) approach for data analyses and determination
of sample size [72]. We will give primacy to differences
in bone formation (measured as percentage change
over baseline) because this is the unique effect of nitro-
glycerin and the one most likely to reduce the risk of
non-vertebral fracture. We wish to be able to estimate
differences between formulations in percentage change
over baseline to within plus or minus 15% assuming a
standard deviation of percentage change of 25%. These
assumptions are based on prior studies of bone turnover
markers that have reported a minimal of 15% change inresponse to treatment and similar changes in SD
[64,73-77].
At the analysis stage, MCB guarantees that differences
between preparations will be estimated to within plus or
15% with 95% confidence (over all the comparisons made).
These intervals result in one of the following conclusions:
(a) a preparation is not the best (that is, does not increase
formation the most), (b) a preparation is better than all
the rest, or (c) the preparation might be best and is within
15% of the best.
At the design stage, MCB guarantees that if the best
preparation is at least 15% better than the next best prep-
aration, it will be ranked as best with probability at least
0.95. Based on these considerations, we require 30 sub-
jects per group or 180 subjects total complete the study.
We assume a dropout of rate of 10% post randomization,
so we will enroll 210 subjects, approximately 35 per group.
If one preparation is determined best by MCB, we will se-
lect that preparation. However, a possible result is that
multiple preparations will be within 15% of the best. In
that case we will rank preferred formulations based on
their acceptability and tolerability; that is, the ISMO tablet
may be preferred for its convenience and familiarity if it is
nearly as good as the best. Thus, MCB allows consider-
ation of other factors in deciding the preparation to be se-
lected. Our MCB strategy allows practical consideration of
ease-of-use and tolerability to guide selection of the prep-
aration for future studies. If two or three preparations have
similar effects on bone formation (do not differ by at least
15%), we will use tolerability data and subject preference
from the run-in and previous studies to guide our choice.
We expect the decision may benefit from the input of ex-
perts in osteoporosis and note that additional studies
might be useful to select an ideal preparation and dose.
Our sample size was determined using STATA V. 10
on the basis of assessing the treatment effect. However,
there is some likelihood we will need to consider other
variables if there are multiple treatments that are within
15% of the best. The limiting factor in comparisons will
be headache prevalence, but with given sample size (420
in the run-in) we will have power of at least 0.8 to detect
a difference in prevalence of 10% with α = 0.05.
Subject recruitment and compliance
We will recruit 420 subjects for our run-in phase. Based
on our prior experience (see below) we anticipate that
50% of these will continue on to the treatment phase.
We anticipate recruiting the 420 subjects for the study
over 24 months (about 4 subjects per week). As we did
for our previous, successful trials, we will advertise in
local newspapers, on local radio and television stations,
and place flyers in doctor’s offices and OP clinics. Poten-
tial subjects will be assessed for eligibility by telephone.
Subjects who meet eligibility criteria and are interested
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to the study center where they will receive written infor-
mation about the study. We have established recruit-
ment goals and timelines that are feasible based on prior
experience. Our previously funded CIHR RCT recruited
four subjects per week. We have maintained these goals
for the current proposal. We are confident that we can
meet this goal for several reasons. Based on our previous
study we have identified methods of highly successful
and efficient recruitment; for example, mailing study in-
formation letters out to women who have had bone min-
eral density tests at Women’s College Hospital, a leading
site for osteoporosis research at the University of
Toronto. Furthermore, our previous study has generated
national and international interest in the lay press (tele-
vision interviews on CTV and radio interviews on CBC’s
Metro Morning) and we will use our contacts with
the press to assist with publicizing our new study. In
addition, all our collaborators have osteoporosis clinics
and will assist in subject recruitment. Finally, and per-
haps most importantly, we will engage both a research
assistant and research associate; hiring an adequate
number of personnel is critical to ensure timely and effi-
cient recruitment and enrolment of study subjects.
As with our previous studies, we will collect and count
medication to assess compliance. Pill counts are a sim-
ple, inexpensive method of monitoring medication com-
pliance and are well correlated (r = 0.69) with electronic
monitoring devices [78]. In our trials, women who had
more than 15% of any pills remaining were classified as
non-compliant.
In our RCT of isosorbide mononitrate, most of the
144 women were compliant with calcium and vitamin D
in the pretreatment phase; 25 women had more than
15% of calcium pills remaining and 26 women had more
than 15% of vitamin D pills remaining. Non-compliance
in the treatment phase was higher, 12 of 48 women
(25%) were non-compliant with placebo and 29 of 96
women (34%) were non-compliant with the intermittent
nitrate. Women who were non-compliant were four
times more likely to report headaches than women who
were compliant [63]. There were 25 dropouts due to
headaches (20 of the 96 randomized to ISMO (21%) and
5 of 48 randomized to placebo (10%) and 6 of the 144
(4%) women did not return to the study center after
randomization and were lost to follow-up [48].
Our RCT of NTG ointment recruited 400 women to
the run-in phase and 243 entered the main trial; this de-
sign (a run-in phase followed by a treatment phase) is
similar to our current study. Note that 65 of 157 (41%)
of subjects did not enter the main trial due to headaches.
Of the 243 women who were randomized 10 of 126 (8%)
participants assigned to NTG and 8 of 117 (7%) subjects
in the discontinued treatment and 2 subjects in each ofthe NTG (2%) and placebo group (2%) were lost to
follow-up [54].
Based on our previous experience (data presented
above) and the experience of our coinvestigators, we es-
timate a 40% dropout rate due to headaches during the
nitrate run-in phase, and a 10% loss to follow-up/non-
compliance rate; this latter estimate is conservative given
that the study is only 12 weeks in duration. Thus, we
will ‘over-recruit’ by 100%; specifically, we will recruit
420 subjects of whom we anticipate that 210 subjects
will complete the run-in phase and enter the treatment
phase (35 per group).
This will be a multicenter trial that will recruit from
five sites: The University Health Network, St Michael’s
Hospital, Women’s College Ambulatory Care Centre,
Sunnybrook Health Sciences Centre, and the Hamilton
Health Sciences Centre at McMaster University. Our
statistician coinvestigator is based at McGill University,
and SRC is based in San Francisco. As well, we will con-
fer with national and international experts on the con-
duct of the trial and the interpretation of our data.
Trial management
SAJ (the primary investigator) will oversee the day-to-day
management of the trials. Two individuals (a research
assistant and a research associate) will be responsible for
the day-to-day management of the study from ethics sub-
missions; subject recruitment, consenting and enrolment;
to spinning, aliquotting and storing blood and urine;
coordinating medication/placebo distribution with the
research pharmacist; data entry and cleaning of data; and
managing the study’s expenses (financial account). This
arrangement is similar to our previous, successful RCTs of
nitrates [48,63].
We will also create a DSMB. All adverse events and clin-
ically important medical conditions will be recorded and
faxed to the committee for adjudication. Subjects will be
discontinued from the study if they develop clinical frac-
tures or if they develop medical conditions that necessitate
starting nitrates (for example, developing angina).
Discussion and conclusions
The number of osteoporotic fractures is increasing
worldwide as the population is aging. Current treat-
ments for osteoporosis are limited by cost, side effects
and most importantly efficacy. Current treatments de-
crease vertebral fractures (which consist of trabecular
bone) but have very limited effects on cortical bone, yet
most osteoporotic fractures occur at these sites (for ex-
ample, the hip, legs, forearm and upper arm). There is a
need for easily administered, inexpensive, well-tolerated
agents that increase bone cortical strength and substan-
tially decrease the risk of fractures. Our data suggest that
organic nitrates may meet this need.
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to establish the efficacy of nitrates for clinical use. To de-
sign and conduct a fracture-prevention trial requires
choosing a preparation and dose of nitrate that maximizes
its beneficial effects on bone while minimizing adverse ef-
fects (headaches). In the current study, we will compare
five widely available nitrate formulations for the efficacy
on markers of bone formation and resorption and for the
number and severity of headache they cause. We will use
this information together with the input of experts in the
treatment of osteoporosis to select a formulation and dose
of nitrate to study in a fracture-prevention trial. Ultim-
ately, our research aims to decrease the burden of illness
due to osteoporotic fractures.
Trial status
This trial was funded by the Canadian Institutes of Health
Research, Physicians' Services Incorporated Foundation
(PSI) and California Pacific Medical Center Research
Institute (CPMC RI). We are currently recruiting study
subjects.
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Additional file 1: Appendix 1. effect of conjugated estrogen and
transdermal nitroglycerin on BMD in ovariectomized rats. Appendix 2.
percentage change in lumbar spine BMD in ovariectomized rats after 12
weeks of treatment with transdermal nitroglycerin. Appendix 3.
differences (mean ± SD) in BMD at the total hip and heel in nitrate users
and non-users (unadjusted and adjusted for estrogen use and baseline
differences). Appendix 4. study design. Appendix 5. NABT inclusion and
exclusion criteria. Appendix 6. NABT Adverse Events Questionnaire.
Appendix 7. NABT Visual Analogue Scale.
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